Clinical Data Key pipeline drug for Lundbeck delivers in Cushing syndrome PharmaphorumLundbeck has reported positive trial results with Cushing's therapy asedebart, a key R D prospect as it faces a patent cliff in the next few years.Rare DiseaseRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) Pharmaphorum Lundbeck has reported positive trial results with Cushing’s therapy asedebart, a key R D prospect as it faces a patent cliff in the next few years. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic diseaseNext: Eisai claims UK grant to expand manufacturing site Related Stories Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026 Clinical Data Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes pharminent June 30, 2026
